• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth - Product Image

Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth

  • ID: 1924268
  • September 2011
  • 151 Pages
  • GBI Research

FEATURED COMPANIES

  • Amgen
  • Baxter International Inc.
  • Bristol-Myers Squibb
  • Sanofi
  • MORE

“Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth” provides in-depth analysis of drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the blood disorders market from 2002 to 2010, forecast forward to 2017.

- Analysis of the leading therapeutic segments, including anemia, thrombosis, neutropenia, hemophilia A, hemophilia B, hemophilia C, READ MORE >

FEATURED COMPANIES

  • Amgen
  • Baxter International Inc.
  • Bristol-Myers Squibb
  • Sanofi
  • MORE

1
1 4
1.1 List of Tables 7
1.2 List of Figures 10
2 Blood Disorders Therapeutics Market to 2017 - Introduction 12
2.1 GBI Research Report Guidance 12
3 Blood Disorders Therpauetics Market to 2017 - Market Overview 13
3.1 Introduction 13
3.1.1 Revenue 13
3.1.2 Annual Cost of Treatment 16
3.1.3 Treatment Usage Patterns 17
3.2 Market Drivers 19
3.2.1 Steady Increase in the Prevalence Population, Particularly in the Top Five Countries of Europe 19
3.2.2 Rapid Uptake of Recombinant Products and Biologics due to Better Efficacy, Safety and Convenient Dosing 19
3.2.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable 20
3.2.4 Increase in Blood Disorders Causing Conditions such as Cancer and Cardiovascular Events 20
3.3 Market Restraints 21
3.3.1 Low Diagnosis Rate as the Contemporary Diagnostic Tools Unable to Diagnose Most Severe Forms of Blood Disorders 21
3.3.2 Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market 21
3.3.3 Clearance of the Regulatory Pathway in the US Will Open up the World’s Largest Pharmaceutical Market to Biosimilar Players 21
3.3.4 Sluggish Growth in the Annual Cost of Treatment for Blood Disorders is Expected to Drive Down the Growth Rate 22
4 Blood Disorders Therapeutics Market to 2017 - Geographical Landscape 23
4.1 Geographical Break-up 23
4.2 The US 25
4.2.1 Revenue 25
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Patterns 27
4.3 Top Five Countries of Europe 30
4.3.1 Revenue 30
4.3.2 Country Segmentation 31
4.3.3 Annual Cost of Treatment 33
4.3.4 Treatment Usage Patterns 34
4.4 Japan 37
4.4.1 Revenue 37
4.4.2 Annual Cost of Treatment 38
4.4.3 Treatment Usage Patterns 39
5 Blood Disorders Therapeutics Market to 2017 - Therapeutic Landscape 41
5.1 Thrombosis Market 41
5.1.1 Introduction 41
5.1.2 Revenue 41
5.1.3 Annual Cost of Treatment 45
5.1.4 Treatment Flow Algorithm 46
5.1.5 Treatment Usage Patterns 47
5.2 Anemia Market 49
5.2.1 Introduction 49
5.2.2 Revenue 50
5.2.3 Annual Cost of Treatment 54
5.2.4 Treatment Flow Algorithm 55
5.2.5 Treatment Usage Patterns 56
5.3 Neutropenia Market 59
5.3.1 Introduction 59
5.3.2 Revenue 60
5.3.3 Annual Cost of Treatment 63
5.3.4 Treatment Flow Algorithm 64
5.3.5 Treatment Usage Patterns 65
5.4 Hemophilia A Market 67
5.4.1 Introduction 67
5.4.2 Revenue 68
5.4.3 Annual Cost of Treatment 72
5.4.4 Treatment Flow Algorithm 73
5.4.5 Treatment Usage Patterns 74
5.5 Hemophilia B Market 76
5.5.1 Introduction 76
5.5.2 Revenue 77
5.5.3 Annual Cost of Treatment 81
5.5.4 Treatment Flow Algorithm 82
5.5.5 Treatment Usage Patterns 83
5.6 Hemophilia C Market 85
5.6.1 Introduction 85
5.6.2 Revenue 86
5.6.3 Annual Cost of Treatment 89
5.6.4 Treatment Flow Algorithm 90
5.6.5 Treatment Usage Patterns 91
5.7 von Willebrand’s Disease (vWD) Market 93
5.7.1 Introduction 93
5.7.2 Revenue 94
5.7.3 Annual Cost of Treatment 97
5.7.4 Treatment Flow Algorithm 98
5.7.5 Treatment Usage Patterns 99
5.8 Alexander’s Disease (Factor VII Deficiency) Market 101
5.8.1 Introduction 101
5.8.2 Revenue 101
5.8.3 Annual Cost of Treatment 105
5.8.4 Treatment Flow Algorithm 106
5.8.5 Treatment Usage Patterns 107
6 Blood Disorders Therapeutics Market to 2017 - Pipeline Analysis 110
6.1 Introduction 110
6.1.1 Research and Development Pipeline – Thrombosis 111
6.1.2 Research and Development Pipeline – Anemia 113
6.1.3 Research and Development Pipeline – Neutropenia 115
6.1.4 Research and Development Pipeline – Hemophilia 117
6.1.5 Research and Development Pipeline – von Willebrand Disease (vWD) 120
6.1.6 Research and Development Pipeline – Alexander’s Disease 121
6.2 Profiles of Promisisng Molecules in the Blood Disorders Market 121
6.2.1 Brilinta/Brilique 121
6.2.2 R744 122
6.2.3 VGX-3200 123
6.2.4 Nupen 124
6.2.5 NecLip-pdFVIII 125
7 Blood Disorders Therapeutics Market to 2017 - Competitive Landscape 126
7.1 Market Share Analysis: Blood Disorders 126
7.2 Competitive Profiling 126
7.2.1 Amgen 126
7.2.2 Bristol-Myers Squibb 128
7.2.3 Sanofi 130
7.2.4 Baxter International Inc. 132
7.2.5 Centocor Ortho Biotech Inc. 133
8 Blood Disorders Therapeutics Market to 2017 - Strategic Consolidations 135
8.1 M&A Deals 135
8.2 Deals by Indication 135
8.3 Deals by Geography 136
8.4 Deals by Value 137
8.5 Major M&A Deals 138
8.5.1 GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 2009 139
8.5.2 Biovitrum AB Acquired Swedish Orphan International AB in November 2009 139
8.5.3 Pfizer Acquired Wyeth in January 2009 139
8.5.4 Baxter International to Acquire Hemophilia-Related Assets from Archemix in November 2010 139
8.5.5 Paul Capital Healthcare Acquires Rights to Xyntha from Dyax in April 2010 140
8.5.6 Baxter Healthcare Acquires Rights to AV513 from Avigen in December 2008 140
8.5.7 Bayer HealthCare Acquires MAXY-VII from Maxygen in July 2008 140
8.5.8 Accredo Health Acquires Hemophilia Resources of America in July 2004 140
8.5.9 CSL Acquires Aventis Behring from Aventis in March 2004 140
8.6 Licensing Agreements 141
8.6.1 Deals by Indication 141
8.6.2 Deals by Geography 142
8.6.3 Deals by Value ($) 143
9 Blood Disorders Therapeutics Market to 2017 - Appendix 144
9.1 Market Definitions 144
9.2 Abbreviations 144
9.3 Research Methodology 145
9.3.1 Coverage 145
9.3.2 Secondary Research 145
9.3.3 Primary Research 146
9.4 Therapeutic Landscape 146
9.4.1 Epidemiology-based Forecasting 147
9.4.2 Market Size by Geography 148
9.5 Geographical Landscape 149
9.6 Pipeline Analysis 149
9.7 Competitive Landscape 149
9.7.1 Expert Panel Validation 149
9.8 Contact Us 149
9.9 Disclaimer 150
9.10 Sources 150

1.1 List of Tables
Table 1: Blood Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 14
Table 2: Blood Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 14
Table 3: Blood Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 16
Table 4: Blood Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 16
Table 5: Blood Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 18
Table 6: Blood Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 18
Table 7: Blood Disorders Therapeutics Market, Revenue Analysis by Geography ($bn), 2002-2010 23
Table 8: Blood Disorders Therapeutics Market, Revenue Analysis by Geography ($bn), 2010-2017 24
Table 9: Blood Disorders Therapeutics Market, The US, Revenue ($bn), 2002–2010 25
Table 10: Blood Disorders Therapeutics Market, The US, Revenue ($bn), 2010–2017 25
Table 11: Blood Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002–2010 26
Table 12: Blood Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2010–2017 26
Table 13: Blood Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002–2010 28
Table 14: Blood Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010–2017 28
Table 15: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002–2010 30
Table 16: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2010–2017 31
Table 17: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002–2010 32
Table 18: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2010–2017 32
Table 19: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002–2010 33
Table 20: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010–2017 34
Table 21: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002–2010 34
Table 22: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010–2017 35
Table 23: Blood Disorders Therapeutics Market, Japan, Revenue ($bn), 2002–2010 37
Table 24: Blood Disorders Therapeutics Market, Japan, Revenue ($bn), 2010–2017 37
Table 25: Blood Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002–2010 38
Table 26: Blood Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010–2017 38
Table 27: Blood Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002–2010 39
Table 28: Blood Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010–2017 40
Table 29: Thrombosis Therapeutics Market, Global, Revenue ($bn), 2002–2010 42
Table 30: Thrombosis Therapeutics Market, Global, Revenue ($bn), 2010–2017 42
Table 31: Thrombosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2010 43
Table 32: Thrombosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010–2017 44
Table 33: Thrombosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 45
Table 34: Thrombosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 46
Table 35: Thrombosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 47
Table 36: Thrombosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 48
Table 37: Anemia Therapeutics Market, Global, Revenue ($bn), 2002–2010 50
Table 38: Anemia Therapeutics Market, Global, Revenue ($bn), 2010–2017 51
Table 39: Anemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2010 52
Table 40: Anemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010–2017 52
Table 41: Anemia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 54
Table 42: Anemia Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 54
Table 43: Anemia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 56
Table 44: Anemia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 57
Table 45: Neutropenia Therapeutics Market, Global, Revenue ($bn), 2002–2010 60
Table 46: Neutropenia Therapeutics Market, Global, Revenue ($bn), 2010–2017 60
Table 47: Neutropenia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2010 61
Table 48: Neutropenia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010–2017 62
Table 49: Neutropenia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 63
Table 50: Neutropenia Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 63
Table 51: Neutropenia Therapeutics Market, Global Treatment Usage Patterns (millions), 2002–2010 65
Table 52: Neutropenia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 65
Table 53: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2002–2010 69
Table 54: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2010–2017 69
Table 55: Hemophilia A Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2010 70
Table 56: Hemophilia A Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010–2017 71
Table 57: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 72
Table 58: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 72
Table 59: Hemophilia A Therapeutics Market, Global Treatment Usage Patterns (thousands), 2002–2010 74
Table 60: Hemophilia A Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 75
Table 61: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2002–2010 78
Table 62: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2010–2017 78
Table 63: Hemophilia B Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 79
Table 64: Hemophilia B Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 80
Table 65: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 81
Table 66: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 82
Table 67: Hemophilia B Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 83
Table 68: Hemophilia B Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 84
Table 69: Hemophilia C Therapeutics Market, Global, Revenue ($m), 2002–2010 86
Table 70: Hemophilia C Therapeutics Market, Global, Revenue ($m), 2010–2017 86
Table 71: Hemophilia C Therapeutics Market, Global, Revenue Analysis by Geography ($’000), 2002–2010 87
Table 72: Hemophilia C Therapeutics Market, Global, Revenue Analysis by Geography ($’000), 2010–2017 88
Table 73: Hemophilia C Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 89
Table 74: Hemophilia C Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 89
Table 75: Hemophilia C Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 91
Table 76: Hemophilia C Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 92
Table 77: vWD Therapeutics Market, Global, Revenue ($m), 2002–2010 94
Table 78: vWD Therapeutics Market, Global, Revenue ($m), 2010–2017 94
Table 79: vWD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 95
Table 80: vWD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 96
Table 81: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 97
Table 82: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 97
Table 83: vWD Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 99
Table 84: vWD Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 100
Table 85: Alexander’s Disease Therapeutics Market, Global, Revenue ($m), 2002–2010 102
Table 86: Alexander’s Disease Therapeutics Market, Global, Revenue ($m), 2010–2017 102
Table 87: Alexander’s Disease Therapeutics Market, Global, Revenue Analysis by Geography, ($m), 2002–2010 103
Table 88: Alexander’s Disease Therapeutics Market, Global, Revenue Analysis by Geography, ($m), 2010–2017 104
Table 89: Alexander’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 105
Table 90: Alexander’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 106
Table 91: Alexander’s Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 107
Table 92: Alexander’s Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 108
Table 93: Thrombosis Therapeutics Market, Global, R&D Pipeline by Phase, 2011 112
Table 94: Anemia Therapeutics Market, Global, R&D Pipeline by Phase, 2011 114
Table 95: Neutropenia Therapeutics Market, Global, R&D Pipeline by Phase, 2011 116
Table 96: Hemophilia Therapeutics Market, Global, R&D Pipeline by Phase, 2011 118
Table 97: vWD Therapeutics Market, Global, R&D Pipeline by Phase, 2011 120
Table 98: Alexander’s Disease Therapeutics Market, Global, R&D Pipeline by Phase, 2011 121
Table 99: Blood Disorders Therapeutics Market, Major M&A Deals 138

1.2 List of Figures
Figure 1: Blood Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 14
Figure 2: Blood Disorders Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017 15
Figure 3: Blood Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 16
Figure 4: Blood Disorders Therapeutics Market, Global, Therapeutic Usage Patterns (millions), 2002–2017 17
Figure 5: Blood Disorders Therapeutics Market, Global, Drivers and Restraints, 2011 20
Figure 6: Blood Disorders Therapeutics Market, Revenue Analysis by Geography ($bn), 2002-2017 23
Figure 7: Blood Disorders Therapeutics Market, The US, Revenue ($bn), 2002–2017 25
Figure 8: Blood Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002–2017 26
Figure 9: Blood Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002–2017 27
Figure 10: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002–2017 30
Figure 11: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002–2017 31
Figure 12: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002–2017 33
Figure 13: Blood Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2002–2017 34
Figure 14: Blood Disorders Therapeutics Market, Japan, Revenue ($bn), 2002–2017 37
Figure 15: Blood Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002–2017 38
Figure 16: Blood Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002–2017 39
Figure 17: Thrombosis Therapeutics Market, Global, Revenue ($bn), 2002–2017 42
Figure 18: Thrombosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2017 43
Figure 19: Thrombosis Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017 44
Figure 20: Thrombosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 45
Figure 21: Thrombosis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 46
Figure 22: Thrombosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 47
Figure 23: Anemia Therapeutics Market, Global, Revenue ($bn), 2002–2017 50
Figure 24: Anemia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2017 51
Figure 25: Anemia Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 53
Figure 26: Anemia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 54
Figure 27: Anemia Therapeutics Market, Global, Treatment Flow Algorithm, 2011 55
Figure 28: Anemia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 56
Figure 29: Neutropenia Therapeutics Market, Global, Revenue ($bn), 2002–2017 60
Figure 30: Neutropenia Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2017 61
Figure 31: Neutropenia Therapeutics Market, Global, Revenue Segmentation, 2010 and 2017 62
Figure 32:Neutropenia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 63
Figure 33: Neutropenia Therapeutics Market, Global, Treatment Flow Algorithm, 2011 64
Figure 34: Neutropenia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 65
Figure 35: Hemophilia A Therapeutics Market, Hemophilia – Disease Cause, 2011 67
Figure 36: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2002–2017 69
Figure 37: Hemophilia A Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2017 70
Figure 38: Hemophilia A Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 71
Figure 39: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 72
Figure 40: Hemophilia A Therapeutics Market, Global, Treatment Flow Algorithm, 2011 73
Figure 41: Hemophilia A Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 74
Figure 42: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2002–2017 78
Figure 43: Hemophilia B Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 79
Figure 44: Hemophilia B Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 80
Figure 45: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 81
Figure 46: Hemophilia B Therapeutics Market, Global, Treatment Flow Algorithm, 2011 82
Figure 47: Hemophilia B Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 83
Figure 48: Hemophilia C Therapeutics Market, Global, Revenue ($m), 2002–2017 86
Figure 49: Hemophilia C Therapeutics Market, Global, Revenue Analysis by Geography ($’000), 2002–2010 87
Figure 50: Hemophilia C Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 88
Figure 51: Hemophilia C Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 89
Figure 52: Hemophilia C Therapeutics Market, Global, Treatment Flow Algorithm, 2011 90
Figure 53: Hemophilia C Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 91
Figure 54: vWD Therapeutics Market, Global, Revenue ($m), 2002–2017 94
Figure 55: vWD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 95
Figure 56: vWD Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 96
Figure 57: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 97
Figure 58: vWD Therapeutics Market, Global, Treatment Flow Algorithm, 2011 98
Figure 59: vWD Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 99
Figure 60: Alexander’s Disease Therapeutics Market, Global, Revenue, 2002–2017 102
Figure 61: Alexander’s Disease Therapeutics Market, Global, Revenue Analysis by Geography, ($m), 2002–2017 103
Figure 62: Alexander’s Disease Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 104
Figure 63: Alexander’s Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 105
Figure 64: Alexander’s Disease Therapeutics Market, Global, Treatment Flow Algorithm, 2011 106
Figure 65: Alexander’s Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 107
Figure 66: Blood Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 110
Figure 67: Thrombosis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 111
Figure 68: Anemia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 113
Figure 69: Neutropenia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 115
Figure 70: Hemophilia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 117
Figure 71: vWD Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 120
Figure 72: Blood Disorders Therapeutics Market, SWOT Analysis, Amgen, 2011 128
Figure 73: Blood Disorders Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 129
Figure 74: Blood Disorders Therapeutics Market, SWOT Analysis, Sanofi, 2011 131
Figure 75: Blood Disorders Therapeutics Market, SWOT Analysis, Baxter International Inc, 2011 133
Figure 76: Blood Disorders Therapeutics Market, SWOT Analysis, Centocor Ortho Biotech Inc, 2011 134
Figure 77: Blood Disorders Therapeutics Market, M&A Deals by Indication (%), 2004-2011 135
Figure 78: Blood Disorders Therapeutics Market, Major Deals By Geography (%), 2004–2010 136
Figure 79: Blood Disorders Therapeutics Market, Deals by Value (%), 2004–2010 137
Figure 80: Blood Disorders Therapeutics Market, Major Licensing Agreements By Indication (%), 2004–2011 141
Figure 81: Blood Disorders Therapeutics Market, Major Licensing Agreements By Geography (%), 2004–2010 142
Figure 82: Blood Disorders Therapeutics Market, Major Licensing Agreements By Deal Value (%), 2004–2010 143
Figure 83: GBI Research Market Forecasting Model 148

FEATURED COMPANIES

  • Amgen
  • Baxter International Inc.
  • Bristol-Myers Squibb
  • Sanofi
  • MORE

“Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth” provides in-depth analysis of the unmet needs, drivers and barriers that affect the global blood disorders therapeutics market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and annual costs of treatment are forecast until 2017 for the key geographic regions in the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

The report is complied using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The Blood Disorders Therapeutics Market is Forecast to Show Moderate Growth Due to a Series of Patent Expiries

In 2010, the global blood disorders market was estimated to be worth $39.4 billion, representing a CAGR of 6.9% between 2002 and 2010. By 2017, the global blood disorders market is expected to reach $50.9 billion, growing at a CAGR of 3.7% between 2010 and 2017. The major reason for this reduced growth rate is the expected decline in the annual cost of treating blood disorders after 2010.

The global blood disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes most of the top selling blockbuster drugs in the anemia, thrombosis, hemophilia, neutropenia and Alexander’s disease markets. The major drugs that are set to lose patent protection between 2010 and 2017 include Kogenate FS in the UK and Germany (2009), NovoSeven (2010), ReFacto (2010), BeneFIX (2011) and Kogenate FS in the US (2014), Plavix (2011), Lovenox (2012), Neupogen (2013), Epogen/Procrit (2013), Aranesp (2014) and Neulasta (2015).

All these drugs together account for approximately $32 billion of revenues in the global blood disorders market.

While the current blood disorders pipeline does offer some promising products, the revenues generated from these products are not expected to completely offset the revenue lost due to patent expiries. Thus, in the future, the overall growth of the global blood disorders market is expected to decline.

- Amgen
- Bristol-Myers Squibb
- Sanofi
- Baxter International Inc.
- Centocor Ortho Biotech Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos